Endometrial receptivity: miRNAs signing in? by Fragouli, E. & Mantzouratou, Anna
Endometrial receptivity:
miRNAs signing in?
Embryo implantation is complex and dependent on various
factors in order to be successful. These factors include female
age, embryo quality and chromosome constitution, endome-
trial receptivity, the female immune system status, and the
embryo transfer method. Repeated implantation failure (RIF)
generally is defined as the failure of a couple to conceive after
the transfer of R10 good-quality embryos or after three
in vitro fertilization (IVF) cycles. The interaction between
the blastocyst and endometrium is critical for a pregnancy
to be established and maintained. This interaction occurs dur-
ing what is known as the window of implantation (WOI),
which is a narrow time frame of maximal endometrial recep-
tivity (reviewed by Craciunas et al. [1]). In recent years,
several approaches have been developed and used clinically
as biomarkers of endometrial receptivity and the WOI. Exam-
ples include endometrial thickness and pattern, Doppler
indices, and the identification of patterns of endometrial
gene expression considered to be representative of its recep-
tive status (1). Another such group of potentially clinically
useful biomarkers are microRNAs (miRNAs) which have
been shown to be involved in the regulation of the genes
responsible for the WOI timing (reviewed by Chen et al. [2]).
In their investigation, Chen et al. (2) used a novel custom-
designed multigene expression profiling platform called
PanelChip to assess the potential usefulness of miRNAs as
biomarkers of endometrial receptivity and the WOI. The plat-
form was based on the use of quantitative real-time polymer-
ase chain reaction. Endometrial biopsies were collected from a
relatively small (n¼ 36) group of infertile women. Most sam-
ples from these biopsies underwent analysis to determine
endometrial receptivity via a commercially available test
(Endometrial Receptivity Analysis [ERA]; Igenomix, Miami,
FL). What the investigators characterized as ‘‘residual endo-
metrial tissues’’ underwent analysis using the PanelChip plat-
form. Of the women included in the study, only very few (13/
36, 36%) were undergoing IVF treatment because of RIF,
while most (23/36, 64%) were classified as the control group.
The control group of women had been able to establish im-
plantation after their first embryo transfer cycle. It also should
be noted that the investigators determined RIF differently
from the conventional definition and included women who
had had two previous failed IVF attempts, instead of three,
in the RIF study group.
The use of the PanelChip assay identified six miRNAs,
namely hsa-miR-155-5p, hsa-miR-20b-5p, hsa-miR-330-
5p, hsa200 miR-718, hsa-miR-940, and hsa-miR-144-3p, ex-
pressed differentially between the RIF (n¼ 8) and control (n¼
17) groups of women. These results were in agreement with
those obtained via the ERA test. In other words, both tests
showed a distinct endometrial expression pattern between
the RIF and control groups of women. Further data analysis
and method validation on a new group of control (n ¼ 6)
and RIF (n¼ 5) women reduced the number of identified miR-
NAs to three. Therefore, the investigators concluded that hsa-
miR-155-5p, hsa-20b-5p, and hsa-miR-718 miRNAs could78most accurately provide a molecular signature to describe
RIF. These findings are, indeed, intriguing and potentially
demonstrate an active role of miRNAs in regulating the
WOI timing. However, the number of analyzed RIF biopsies
was small, and the study itself examined patients undergoing
treatment in a single IVF clinic, rather than in multiple clinics.
The usefulness of the identified miRNAs would have been
more evident if they were found to be common among larger
groups of women being treated for RIF in several IVF clinics.
Studies that aspire to develop clinically useful biomarkers
for prognostic and diagnostic purposes require highly selected
and targeted patient cohorts that can act as training sets for
algorithmic selection and as validation in either the control
or test cohorts. Deciphering these appropriate cohorts in hu-
man reproductive studies usually is very difficult as there
are several factors or variables to be considered. With this
in mind, future directions could include establishing stan-
dardized training and validation datasets that can be applied
to multiple research projects relating to biomarkers of RIF, as
individual patient variability and small patient cohorts risk
leading to transient and not reproducible conclusions (3).
Standardization is especially crucial in the study of miRNAs,
as their transient and regulatory nature implies that vari-
ability in their levels will exist in the same patient depending
on the timing of sample collection, and within patient cohorts
as their hormone responses and genomes will vary signifi-
cantly. The function of miRNAs in reproduction is complex.
This probably is the reason why Chen et al. (2) were not
able to establish many common miRNAs with other studies
as they point out in their investigation.
Currently, the ERA test is the one that has been used most
widely to predict endometrial receptivity (4, 5). Studies using
this test and performing a personalized embryo transfer (pET),
according to its results generally have reported positive clin-
ical outcomes. One of these studies determined that women
with RIF have a higher rate of nonreceptive endometrium
(26%) when compared with women without RIF (12%). These
findings are echoed in the study of Chen et al. (2). Moreover, a
recently published multicenter randomized controlled trial
(RCT) examining the clinical effectiveness of pET after the
ERA test, reported a statistically significant improvement in
outcomes, such as pregnancy, implantation, and cumulative
live birth rates, when pET took place, compared with frozen
and fresh embryo transfers. These results are encouraging
and further illustrate the value of predicting endometrial
receptivity during IVF. It is of note, however, that the patient
dropout rate for this RCT was higher than what was expected
initially.
It is evident from published studies that one of the main
causes of RIF is issues with endometrial receptivity and the
timing of the WOI. These findings were confirmed further in
the investigation performed by Chen et al. (2), who identified
three miRNAs that could provide an endometrial signature for
RIF with an accuracy of approximately 91%.MicroRNAs have
been identified previously as potentially useful biomarkers of,
for example, embryo viability, but there was a lack of
consensus in the identified miRNAmolecules among different
studies. The results in the investigation by Chen et al. (2) areVOL. 116 NO. 1 / JULY 2021
Fertility and Sterility®fascinating. However, the three miRNAs determined to be
possible RIF endometrial biomarkers will need to be verified
further in larger groups of patients, having treatment in mul-
tiple IVF clinics, and in an RCT setting to clearly determine
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